Bioxytran, INC Form 4 insider transactions

BIOXYTRAN Director Alan M. Hoberman reported multiple acquisitions of preferred and common stock in the company, increasing his direct beneficial ownership.

BIOXYTRAN Director Radka Milanova acquired additional preferred shares in two separate transactions, increasing her beneficial ownership.

BIOXYTRAN Director Dale H. Conaway reported two separate acquisitions of preferred shares, increasing his beneficial ownership to 379,177 shares.

BIOXYTRAN Director Anders Utter acquired 38,588 preferred shares at $0.35, increasing his beneficial ownership to 372,580 shares.

BIOXYTRAN CEO David Platt amended his beneficial ownership, acquiring 11.4 million preferred shares as payment for the sale of NDPD to Bioxytran, while 14 million indirect shares were cancelled.

Bioxytran's Chief Commercial Officer and 10% owner, Michael Sheikh, acquired 6,614,720 preferred shares at $0.545 each as payment for the sale of NDPD Pharma to Bioxytran.

Bioxytran CFO Ola Soderquist acquired over 10 million preferred shares as payment for NDPD Pharma and converted preferred stock to common shares.

Bioxytran director Radka Milanova acquired 97,535 shares of common stock at a price of $0.315 per share on January 6, 2025.

Bioxytran director Dale Conaway acquired 97,535 shares of preferred stock at $0.315 per share on January 6, 2025.

Bioxytran director Alan Hoberman acquired 97,535 preferred shares at $0.315 per share on January 6, 2025.

Bioxytran director Anders Utter acquired 97,535 shares of the company's stock at a price of $0.315 per share on January 6, 2025.

Radka Milanova, a director at Bioxytran, Inc., reported acquiring and disposing of preferred stock on October 25, 2024.

David Platt, CEO of Bioxytran, Inc., reports changes in his beneficial ownership of the company's preferred stock due to a return of shares to treasury and shares issued as payment for the sale of NDPD Pharma to Bioxytran.

Anders Utter, a director at Bioxytran, Inc. (BIXT), acquired 20,619 preferred shares at $0.46 per share on October 25, 2024.

Michael Sheikh, Chief Communications Officer of Bioxytran, reports acquiring and disposing of preferred shares in a transaction related to the sale of NDPD Pharma.

Director Dale H. Conaway reports acquiring 20,619 shares of preferred stock at $0.46 each and disposing of 232,637 shares.

Ola Soderquist, CFO of Bioxytran, Inc., reports acquisition and disposal of preferred and common stock related to the sale of NDPD Pharma and a stock exchange.

Director Alan Hoberman reports acquiring and disposing of Bioxytran, Inc. preferred stock on October 25, 2024.

Ola Soderquist, CFO of Bioxytran, Inc., executed a 5:1 exchange of common stock for convertible preferred stock on August 19, 2024.

Michael Sheikh, Chief Communications Officer of Bioxytran, Inc., exchanged 8,000,000 shares of common stock for 1,600,000 shares of convertible preferred stock in a 5:1 exchange.

Director Radka Milanova reports acquisition and disposal of Bioxytran, Inc. common and preferred stock.

Bioxytran CEO David Platt reports a series of transactions involving common and preferred stock, including acquisitions, disposals, and conversions, impacting his beneficial ownership.

Anders Utter, a director at Bioxytran, Inc., executed a 5:1 exchange of common stock for convertible preferred stock and reported transactions involving the company's securities.

Director Dale Conaway converted common stock into convertible preferred stock in Bioxytran, Inc.

Director Alan Hoberman converted common stock into convertible preferred stock in a 5:1 exchange.

Radka Milanova, a director of Bioxytran, Inc. (BIXT), reported the acquisition of 70,423 shares of common stock at a price of $0.142 per share on April 19, 2024.

Director Dale H. Conaway reports the acquisition of 70,423 shares of Bioxytran, Inc. common stock at a price of $0.142 per share on April 19, 2024.

Director Alan Hoberman reports acquiring and disposing of Bioxytran, Inc. (BIXT) common stock on April 19, 2024.

Director Anders Utter acquired 266,955 shares of Bioxytran, Inc. at $0.114 per share on March 27, 2024.

Director Dale H. Conaway increased his holdings in Bioxytran, Inc. by acquiring 266,955 shares of common stock at $0.114 per share on March 27, 2024.